Drug Profile
Durvalumab - Celgene/MedImmune
Alternative Names: Anti-PD-L1 monoclonal antibody; Anti-PD-LI mAb; Anti-programmed cell death 1 ligand 1 monoclonal antibody; Imfimzi; Imfinzi; MEDI-4736Latest Information Update: 14 Mar 2024
Price :
$50
*
At a glance
- Originator MedImmune
- Developer AIO Studien gGmbH; AstraZeneca; AVEO Oncology; Big Ten Cancer Research Consortium; Biocompatibles International; Canadian Cancer Trials Group; Cancer Research UK; Case Comprehensive Cancer Center; Celgene Corporation; Celgene International SARL; Centre hospitalier de l'Universite de Montreal; Centre Leon Berard; Charite - Universitatsmedizin Berlin; Childrens Hospital Los Angeles; Daiichi Sankyo Company; Dana-Farber Cancer Institute; Eli Lilly and Company; European Network of Gynaecological Oncological Trial Groups; Fondazione IRCCS Istituto Nazionale dei Tumori; Gradalis; Grand Hopital de Charleroi; Grupo Espanol de Tumores Neuroendocrinos; GSK; Gustave Roussy; Immunocore; Innate Pharma; Institut Claudius Regaud; Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori; Jules Bordet Institute; Juno Therapeutics; Kyoto Breast Cancer Research Network; Ludwig Institute for Cancer Research; M. D. Anderson Cancer Center; MedImmune; Memorial Sloan-Kettering Cancer Center; Mirati Therapeutics; Myriad Genetic Laboratories; National Cancer Institute (USA); National Health and Medical Research Council; NHS Greater Glasgow and Clyde; Nordic Society of Gynaecological - Clinical Trial Unit; Northwestern University; Pharmacyclics; Radboud University; Samsung Medical Center; Spanish Oncology Genito-Urinary Group; Swiss Group for Clinical Cancer Research; SWOG; UNC Lineberger Comprehensive Cancer Center; Undisclosed; UNICANCER; University College London; University Health Network; University of Colorado at Denver; University of Kansas Medical Center; University of Maryland Greenbaum Cancer Center; University of Southern California; University of Sydney; University of Texas M. D. Anderson Cancer Center; VentiRx Pharmaceuticals; Washington University School of Medicine; Yale University; Yonsei University College of Medicine
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer; Small cell lung cancer
- Registered Biliary cancer; Liver cancer; Urogenital cancer
- Phase III Bladder cancer; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; Malignant-mesothelioma; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer
- Phase II/III Pancreatic cancer
- Phase II Acute myeloid leukaemia; Brain metastases; Breast cancer; Cholangiocarcinoma; Colorectal cancer; Diffuse large B cell lymphoma; Gallbladder cancer; Germ cell cancer; Glioblastoma; HER2 negative breast cancer; Malignant melanoma; Multiple myeloma; Myelodysplastic syndromes; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Oropharyngeal cancer; Prostate cancer; Sarcoma; Soft tissue sarcoma; Squamous cell cancer; Uterine cancer
- Phase I/II Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Haematological malignancies; Lung cancer; Lymphoma; Peripheral T-cell lymphoma; Renal cancer
- No development reported CNS cancer; Gastrointestinal cancer; Lymphoproliferative disorders; Thyroid cancer; Vulvovaginal cancer
Most Recent Events
- 01 Mar 2024 AstraZeneca suspends phase II SOUND trial in Non-small cell lung cancer (Combination therapy, In adults, In children, In adolescents, In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) to evaluate risks and benefits of the study (NCT05374603)
- 22 Feb 2024 Phase-II clinical trials in Non-small cell lung cancer (In adults, In the elderly, Neoadjuvant therapy, First-line therapy) in USA, Sweden, Spain, Portugal, Italy, Hungary, Germany, France, Czech Republic, Canada, Austria (IV) ( NCT05925530)
- 13 Feb 2024 Phase-II clinical trials in Liver cancer (Combination therapy, Inoperable/Unresectable, First-line therapy) in USA (IV) (NCT06040099)